Exploration
Accueil
Racine
Exploration
Accueil

Serveur d'exploration COVID et hydrochloroquine

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Severe COVID-19 in pediatric age: an update on the role of the anti-rheumatic agents.

Identifieur interne : 000145 ( Main/Exploration ); précédent : 000144; suivant : 000146

Severe COVID-19 in pediatric age: an update on the role of the anti-rheumatic agents.

Auteurs : Giorgio Costagliola [Italie] ; Erika Spada [Italie] ; Rita Consolini [Italie]

Source :

RBID : pubmed:33947420

Descripteurs français

English descriptors

Abstract

BACKGROUND

SARS-CoV-2 can induce an immune impairment and dysregulation, finally resulting in the massive release of inflammatory mediators (cytokine storm), strongly contributing to the pulmonary and systemic manifestations in severe coronavirus disease 2019 (COVID-19). As a consequence, different drugs active on the immune system have been proposed for the treatment of the disease in adults.

ROLE OF THE ANTI-RHEUMATIC AGENTS IN CHILDREN

Children are more likely to develop a mild disease course, as the severe form of COVID-19 is identified in less than 5% of the pediatric patients. Moreover, in children a peculiar disease phenotype, defined as multisystem inflammatory syndrome in children (MIS-C) is observed, representing the most severe expression of the inflammatory dysregulation caused by SARS-CoV-2. The limited experience with the severe pediatric COVID-19 and MIS-C does not allow conclusions about the role of the immune pharmacological approach, and therefore the treatment of these conditions represents a considerable clinical challenge. The use of chloroquine, hydroxychloroquine, and colchicine in the early disease stages is not sufficiently supported by evidence, and there is an increasing interest in the role of biologic agents, including anti-IL-1 and anti-IL-6 agents, in the prevention and treatment of the severe manifestations of COVID-19.

CONCLUSION

The therapeutic approach to pediatric COVID-19 is multidisciplinary, and anti-rheumatic agents have a prominent role in severe disease. This paper reviews the rationale for the use of anti-rheumatic agents in pediatric COVID-19 and MIS-C and the clinical experience with the single drugs. Finally, the areas of potential improvement in the use of anti-rheumatic agents, including the optimization of the drug choice and the timing of administration, are discussed.


DOI: 10.1186/s12969-021-00559-5
PubMed: 33947420
PubMed Central: PMC8094984


Affiliations:

Links toward previous steps (curation, corpus...)

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Severe COVID-19 in pediatric age: an update on the role of the anti-rheumatic agents.</title>
<author>
<name sortKey="Costagliola, Giorgio" sort="Costagliola, Giorgio" uniqKey="Costagliola G" first="Giorgio" last="Costagliola">Giorgio Costagliola</name>
<affiliation wicri:level="4">
<nlm:affiliation>Section of Rheumatology and Clinical Immunology, Division of Pediatrics, Department of Clinical and Experimental Medicine, University of Pisa, Via Roma 67, 56126, Pisa, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Section of Rheumatology and Clinical Immunology, Division of Pediatrics, Department of Clinical and Experimental Medicine, University of Pisa, Via Roma 67, 56126, Pisa</wicri:regionArea>
<placeName>
<settlement type="city">Pise</settlement>
<region nuts="2">Toscane</region>
</placeName>
<orgName type="university">Université de Pise</orgName>
</affiliation>
</author>
<author>
<name sortKey="Spada, Erika" sort="Spada, Erika" uniqKey="Spada E" first="Erika" last="Spada">Erika Spada</name>
<affiliation wicri:level="4">
<nlm:affiliation>Section of Rheumatology and Clinical Immunology, Division of Pediatrics, Department of Clinical and Experimental Medicine, University of Pisa, Via Roma 67, 56126, Pisa, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Section of Rheumatology and Clinical Immunology, Division of Pediatrics, Department of Clinical and Experimental Medicine, University of Pisa, Via Roma 67, 56126, Pisa</wicri:regionArea>
<placeName>
<settlement type="city">Pise</settlement>
<region nuts="2">Toscane</region>
</placeName>
<orgName type="university">Université de Pise</orgName>
</affiliation>
</author>
<author>
<name sortKey="Consolini, Rita" sort="Consolini, Rita" uniqKey="Consolini R" first="Rita" last="Consolini">Rita Consolini</name>
<affiliation wicri:level="4">
<nlm:affiliation>Section of Rheumatology and Clinical Immunology, Division of Pediatrics, Department of Clinical and Experimental Medicine, University of Pisa, Via Roma 67, 56126, Pisa, Italy. rita.consolini@med.unipi.it.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Section of Rheumatology and Clinical Immunology, Division of Pediatrics, Department of Clinical and Experimental Medicine, University of Pisa, Via Roma 67, 56126, Pisa</wicri:regionArea>
<placeName>
<settlement type="city">Pise</settlement>
<region nuts="2">Toscane</region>
</placeName>
<orgName type="university">Université de Pise</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2021">2021</date>
<idno type="RBID">pubmed:33947420</idno>
<idno type="pmid">33947420</idno>
<idno type="doi">10.1186/s12969-021-00559-5</idno>
<idno type="pmc">PMC8094984</idno>
<idno type="wicri:Area/Main/Corpus">000054</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000054</idno>
<idno type="wicri:Area/Main/Curation">000054</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000054</idno>
<idno type="wicri:Area/Main/Exploration">000054</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Severe COVID-19 in pediatric age: an update on the role of the anti-rheumatic agents.</title>
<author>
<name sortKey="Costagliola, Giorgio" sort="Costagliola, Giorgio" uniqKey="Costagliola G" first="Giorgio" last="Costagliola">Giorgio Costagliola</name>
<affiliation wicri:level="4">
<nlm:affiliation>Section of Rheumatology and Clinical Immunology, Division of Pediatrics, Department of Clinical and Experimental Medicine, University of Pisa, Via Roma 67, 56126, Pisa, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Section of Rheumatology and Clinical Immunology, Division of Pediatrics, Department of Clinical and Experimental Medicine, University of Pisa, Via Roma 67, 56126, Pisa</wicri:regionArea>
<placeName>
<settlement type="city">Pise</settlement>
<region nuts="2">Toscane</region>
</placeName>
<orgName type="university">Université de Pise</orgName>
</affiliation>
</author>
<author>
<name sortKey="Spada, Erika" sort="Spada, Erika" uniqKey="Spada E" first="Erika" last="Spada">Erika Spada</name>
<affiliation wicri:level="4">
<nlm:affiliation>Section of Rheumatology and Clinical Immunology, Division of Pediatrics, Department of Clinical and Experimental Medicine, University of Pisa, Via Roma 67, 56126, Pisa, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Section of Rheumatology and Clinical Immunology, Division of Pediatrics, Department of Clinical and Experimental Medicine, University of Pisa, Via Roma 67, 56126, Pisa</wicri:regionArea>
<placeName>
<settlement type="city">Pise</settlement>
<region nuts="2">Toscane</region>
</placeName>
<orgName type="university">Université de Pise</orgName>
</affiliation>
</author>
<author>
<name sortKey="Consolini, Rita" sort="Consolini, Rita" uniqKey="Consolini R" first="Rita" last="Consolini">Rita Consolini</name>
<affiliation wicri:level="4">
<nlm:affiliation>Section of Rheumatology and Clinical Immunology, Division of Pediatrics, Department of Clinical and Experimental Medicine, University of Pisa, Via Roma 67, 56126, Pisa, Italy. rita.consolini@med.unipi.it.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Section of Rheumatology and Clinical Immunology, Division of Pediatrics, Department of Clinical and Experimental Medicine, University of Pisa, Via Roma 67, 56126, Pisa</wicri:regionArea>
<placeName>
<settlement type="city">Pise</settlement>
<region nuts="2">Toscane</region>
</placeName>
<orgName type="university">Université de Pise</orgName>
</affiliation>
</author>
</analytic>
<series>
<title level="j">Pediatric rheumatology online journal</title>
<idno type="eISSN">1546-0096</idno>
<imprint>
<date when="2021" type="published">2021</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Antirheumatic Agents (pharmacology)</term>
<term>Biological Factors (pharmacology)</term>
<term>COVID-19 (complications)</term>
<term>COVID-19 (drug therapy)</term>
<term>COVID-19 (immunology)</term>
<term>COVID-19 (prevention & control)</term>
<term>Child (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Systemic Inflammatory Response Syndrome (immunology)</term>
<term>Systemic Inflammatory Response Syndrome (prevention & control)</term>
<term>Treatment Outcome (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Antirhumatismaux (pharmacologie)</term>
<term>Enfant (MeSH)</term>
<term>Facteurs biologiques (pharmacologie)</term>
<term>Humains (MeSH)</term>
<term>Résultat thérapeutique (MeSH)</term>
<term>Syndrome de réponse inflammatoire généralisée (immunologie)</term>
<term>Syndrome de réponse inflammatoire généralisée (prévention et contrôle)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en">
<term>Antirheumatic Agents</term>
<term>Biological Factors</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en">
<term>COVID-19</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en">
<term>COVID-19</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr">
<term>Syndrome de réponse inflammatoire généralisée</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en">
<term>COVID-19</term>
<term>Systemic Inflammatory Response Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr">
<term>Antirhumatismaux</term>
<term>Facteurs biologiques</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en">
<term>COVID-19</term>
<term>Systemic Inflammatory Response Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr">
<term>Syndrome de réponse inflammatoire généralisée</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Child</term>
<term>Humans</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Enfant</term>
<term>Humains</term>
<term>Résultat thérapeutique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">
<p>
<b>BACKGROUND</b>
</p>
<p>SARS-CoV-2 can induce an immune impairment and dysregulation, finally resulting in the massive release of inflammatory mediators (cytokine storm), strongly contributing to the pulmonary and systemic manifestations in severe coronavirus disease 2019 (COVID-19). As a consequence, different drugs active on the immune system have been proposed for the treatment of the disease in adults.</p>
</div>
<div type="abstract" xml:lang="en">
<p>
<b>ROLE OF THE ANTI-RHEUMATIC AGENTS IN CHILDREN</b>
</p>
<p>Children are more likely to develop a mild disease course, as the severe form of COVID-19 is identified in less than 5% of the pediatric patients. Moreover, in children a peculiar disease phenotype, defined as multisystem inflammatory syndrome in children (MIS-C) is observed, representing the most severe expression of the inflammatory dysregulation caused by SARS-CoV-2. The limited experience with the severe pediatric COVID-19 and MIS-C does not allow conclusions about the role of the immune pharmacological approach, and therefore the treatment of these conditions represents a considerable clinical challenge. The use of chloroquine, hydroxychloroquine, and colchicine in the early disease stages is not sufficiently supported by evidence, and there is an increasing interest in the role of biologic agents, including anti-IL-1 and anti-IL-6 agents, in the prevention and treatment of the severe manifestations of COVID-19.</p>
</div>
<div type="abstract" xml:lang="en">
<p>
<b>CONCLUSION</b>
</p>
<p>The therapeutic approach to pediatric COVID-19 is multidisciplinary, and anti-rheumatic agents have a prominent role in severe disease. This paper reviews the rationale for the use of anti-rheumatic agents in pediatric COVID-19 and MIS-C and the clinical experience with the single drugs. Finally, the areas of potential improvement in the use of anti-rheumatic agents, including the optimization of the drug choice and the timing of administration, are discussed.</p>
</div>
</front>
</TEI>
<pubmed>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">33947420</PMID>
<DateCompleted>
<Year>2021</Year>
<Month>05</Month>
<Day>18</Day>
</DateCompleted>
<DateRevised>
<Year>2021</Year>
<Month>05</Month>
<Day>18</Day>
</DateRevised>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Electronic">1546-0096</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>19</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2021</Year>
<Month>May</Month>
<Day>04</Day>
</PubDate>
</JournalIssue>
<Title>Pediatric rheumatology online journal</Title>
<ISOAbbreviation>Pediatr Rheumatol Online J</ISOAbbreviation>
</Journal>
<ArticleTitle>Severe COVID-19 in pediatric age: an update on the role of the anti-rheumatic agents.</ArticleTitle>
<Pagination>
<MedlinePgn>68</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1186/s12969-021-00559-5</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">SARS-CoV-2 can induce an immune impairment and dysregulation, finally resulting in the massive release of inflammatory mediators (cytokine storm), strongly contributing to the pulmonary and systemic manifestations in severe coronavirus disease 2019 (COVID-19). As a consequence, different drugs active on the immune system have been proposed for the treatment of the disease in adults.</AbstractText>
<AbstractText Label="ROLE OF THE ANTI-RHEUMATIC AGENTS IN CHILDREN" NlmCategory="UNASSIGNED">Children are more likely to develop a mild disease course, as the severe form of COVID-19 is identified in less than 5% of the pediatric patients. Moreover, in children a peculiar disease phenotype, defined as multisystem inflammatory syndrome in children (MIS-C) is observed, representing the most severe expression of the inflammatory dysregulation caused by SARS-CoV-2. The limited experience with the severe pediatric COVID-19 and MIS-C does not allow conclusions about the role of the immune pharmacological approach, and therefore the treatment of these conditions represents a considerable clinical challenge. The use of chloroquine, hydroxychloroquine, and colchicine in the early disease stages is not sufficiently supported by evidence, and there is an increasing interest in the role of biologic agents, including anti-IL-1 and anti-IL-6 agents, in the prevention and treatment of the severe manifestations of COVID-19.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The therapeutic approach to pediatric COVID-19 is multidisciplinary, and anti-rheumatic agents have a prominent role in severe disease. This paper reviews the rationale for the use of anti-rheumatic agents in pediatric COVID-19 and MIS-C and the clinical experience with the single drugs. Finally, the areas of potential improvement in the use of anti-rheumatic agents, including the optimization of the drug choice and the timing of administration, are discussed.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Costagliola</LastName>
<ForeName>Giorgio</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Section of Rheumatology and Clinical Immunology, Division of Pediatrics, Department of Clinical and Experimental Medicine, University of Pisa, Via Roma 67, 56126, Pisa, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Spada</LastName>
<ForeName>Erika</ForeName>
<Initials>E</Initials>
<AffiliationInfo>
<Affiliation>Section of Rheumatology and Clinical Immunology, Division of Pediatrics, Department of Clinical and Experimental Medicine, University of Pisa, Via Roma 67, 56126, Pisa, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Consolini</LastName>
<ForeName>Rita</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Section of Rheumatology and Clinical Immunology, Division of Pediatrics, Department of Clinical and Experimental Medicine, University of Pisa, Via Roma 67, 56126, Pisa, Italy. rita.consolini@med.unipi.it.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2021</Year>
<Month>05</Month>
<Day>04</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Pediatr Rheumatol Online J</MedlineTA>
<NlmUniqueID>101248897</NlmUniqueID>
<ISSNLinking>1546-0096</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018501">Antirheumatic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001685">Biological Factors</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList>
<SupplMeshName Type="Disease" UI="C000705967">pediatric multisystem inflammatory disease, COVID-19 related</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName UI="D018501" MajorTopicYN="N">Antirheumatic Agents</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D001685" MajorTopicYN="N">Biological Factors</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D018746" MajorTopicYN="Y">Systemic Inflammatory Response Syndrome</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Anakinra</Keyword>
<Keyword MajorTopicYN="N">Canakinumab</Keyword>
<Keyword MajorTopicYN="N">Children</Keyword>
<Keyword MajorTopicYN="N">Coronavirus</Keyword>
<Keyword MajorTopicYN="N">Macrophage activation syndrome</Keyword>
<Keyword MajorTopicYN="N">Multisystem inflammatory syndrome in children</Keyword>
<Keyword MajorTopicYN="N">SARS-CoV-2</Keyword>
<Keyword MajorTopicYN="N">Tocilizumab</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="received">
<Year>2020</Year>
<Month>11</Month>
<Day>13</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted">
<Year>2021</Year>
<Month>04</Month>
<Day>16</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2021</Year>
<Month>5</Month>
<Day>5</Day>
<Hour>5</Hour>
<Minute>42</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2021</Year>
<Month>5</Month>
<Day>6</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2021</Year>
<Month>5</Month>
<Day>19</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">33947420</ArticleId>
<ArticleId IdType="doi">10.1186/s12969-021-00559-5</ArticleId>
<ArticleId IdType="pii">10.1186/s12969-021-00559-5</ArticleId>
<ArticleId IdType="pmc">PMC8094984</ArticleId>
</ArticleIdList>
<ReferenceList>
<Reference>
<Citation>N Engl J Med. 2020 Jul 23;383(4):334-346</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32598831</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Front Pediatr. 2019 May 21;7:202</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">31165053</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2020 Nov 19;383(21):2030-2040</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">33031652</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Pediatr Infect Dis J. 2020 Jun;39(6):469-477</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32398569</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>World J Pediatr. 2020 Jun;16(3):232-239</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32333248</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Invest. 2020 May 1;130(5):2620-2629</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32217835</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Eur J Pediatr. 2020 Jul;179(7):1029-1046</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32424745</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Arthritis Res Ther. 2017 Jan 23;19(1):13</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">28115015</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Paediatr Respir Rev. 2020 Aug 11;:</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32891582</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet Respir Med. 2021 Mar;9(3):295-304</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">33493450</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Autoimmun Rev. 2020 Jul;19(7):102568</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32376398</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Ultrasound Med. 2020 Jul;39(7):1459-1462</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32198775</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Chim Acta. 2020 Jul;506:145-148</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32178975</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Infect. 2020 Aug;81(2):e16-e25</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32335169</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Am J Pathol. 2021 Jan;191(1):90-107</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">33157066</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Immun Inflamm Dis. 2021 Feb 10;:</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">33566457</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>JAMA Intern Med. 2021 Jan 1;181(1):41-51</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">33080002</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Semin Arthritis Rheum. 2019 Dec;49(3):459-463</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">31255241</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Ann Intern Med. 2020 Oct 20;173(8):623-631</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32673060</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Int J Antimicrob Agents. 2020 May;55(5):105938</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32171740</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Pediatr Gastroenterol Nutr. 2020 Aug;71(2):153-155</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32452979</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Exp Pediatr. 2020 Apr;63(4):117-118</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32272008</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Rheumatol. 2020 Jul;39(7):2055-2062</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32277367</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Infect Dis. 2020 Apr 27;:</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32338708</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nat Rev Immunol. 2020 Aug;20(8):453-454</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32546853</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet. 2020 Feb 15;395(10223):e30-e31</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32032529</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>JAMA Pediatr. 2020 Sep 1;174(9):825-826</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32379296</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Int J Antimicrob Agents. 2020 Sep;56(3):106103</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32712333</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>MMWR Morb Mortal Wkly Rep. 2020 Apr 10;69(14):422-426</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32271728</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Curr Treatm Opt Rheumatol. 2017 Mar;3(1):33-48</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">28944163</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Front Public Health. 2020 May 08;8:186</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32574290</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Immunol. 2020 Aug;217:108490</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32492478</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2020 Aug 6;383(6):517-525</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32492293</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Ann Rheum Dis. 2019 Oct;78(10):1357-1362</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">31296501</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Microbiol Infect. 2018 Jun;24 Suppl 2:S21-S40</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">29447987</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Ann Rheum Dis. 2020 Oct;79(10):1381-1382</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32376597</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Exp Med. 2007 Jan 22;204(1):11-5</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17227911</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>JAMA. 2020 Oct 6;324(13):1307-1316</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32876695</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cureus. 2020 Jul 7;12(7):e9038</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32656044</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nat Rev Rheumatol. 2020 Mar;16(3):155-166</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32034323</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>JAMA. 2020 Apr 28;323(16):1582-1589</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32219428</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Ital J Pediatr. 2021 Feb 15;47(1):32</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">33588905</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet Child Adolesc Health. 2021 Feb;5(2):133-141</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32956615</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Travel Med Infect Dis. 2020 Mar - Apr;34:101623</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32179124</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Exp Rheumatol. 2020 Mar-Apr;38(2):175-180</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32207680</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Med Virol. 2020 Jul;92(7):791-796</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32181911</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Infect Chemother. 2015 Mar;47(1):12-26</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25844259</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Rheumatol. 2019 Apr;46(4):416-421</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">30647180</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell. 2020 Nov 12;183(4):968-981.e7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32966765</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Open Forum Infect Dis. 2020 Mar 21;7(3):ofaa102</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32258207</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>World J Pediatr. 2020 Jun;16(3):251-259</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32193831</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Chest. 2021 Mar;159(3):933-948</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">33075378</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>JAMA. 2020 Jun 23;323(24):2493-2502</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32392282</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Ther. 2019 Sep;41(9):1823-1838.e4</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">31470986</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Autoimmun Rev. 2020 May;19(5):102523</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32205186</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>PLoS One. 2020 Mar 19;15(3):e0230548</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32191764</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet Rheumatol. 2020 Oct;2(10):e592</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32929415</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Int J Mol Sci. 2019 Apr 17;20(8):</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">30999610</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nat Rev Rheumatol. 2020 Aug;16(8):465-470</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32561873</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Diabetes Metab Syndr. 2020 Jul - Aug;14(4):589-596</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32417708</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell Host Microbe. 2020 Jun 10;27(6):870-878</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32464097</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Ann Rheum Dis. 2016 Mar;75(3):481-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">26865703</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Traffic. 2008 Sep;9(10):1791-800</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18657069</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Virus Res. 2020 Sep;286:198070</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32569708</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>JAMA Netw Open. 2020 Jun 1;3(6):e2013136</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32579195</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Chem Lab Med. 2020 Jun 25;58(7):1021-1028</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32286245</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet. 2020 Jun 6;395(10239):1771-1778</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32410760</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet Rheumatol. 2020 Jun;2(6):e358-e367</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32373790</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Int Immunopharmacol. 2021 Feb;91:107262</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">33338863</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cochrane Database Syst Rev. 2020 Oct 12;10:CD013600</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">33044747</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nat Rev Microbiol. 2017 Jan;15(1):55-63</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">27694885</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Crit Care Med. 2016 Feb;44(2):275-81</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">26584195</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Virus Res. 2007 Sep;128(1-2):1-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17532082</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Rheumatology (Oxford). 2020 Jul 1;59(7):1769-1770</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32472681</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Front Pediatr. 2021 Jan 06;8:620621</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">33490003</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Exp Pediatr. 2020 Jul;63(7):239-250</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32664709</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Curr Cardiol Rep. 2018 Jun 14;20(8):61</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">29904899</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Drug Investig. 2020 Jul;40(7):591-601</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32468425</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Allergy Clin Immunol. 2020 Jul;146(1):213-215</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32437739</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Invest. 2020 Nov 2;130(11):5942-5950</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32701511</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Front Pediatr. 2020 Sep 11;8:574</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">33042918</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet. 2020 Mar 28;395(10229):1033-1034</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32192578</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Int J Infect Dis. 2020 Oct;99:291-297</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32768693</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet Child Adolesc Health. 2020 Sep;4(9):653-661</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32593339</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>United European Gastroenterol J. 2021 Mar;9(2):159-176</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">33210980</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet Respir Med. 2020 May;8(5):475-481</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32105632</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Int J Mol Sci. 2017 Feb 11;18(2):</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">28208675</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Front Oncol. 2020 Jan 31;9:1529</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32076597</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2021 Jan 7;384(1):20-30</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">33332779</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Immunol. 2020 May;214:108393</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32222466</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Children (Basel). 2020 Jul 01;7(7):</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32630212</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet Rheumatol. 2020 Jun;2(6):e325-e331</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32501454</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Exp Rheumatol. 2020 Mar-Apr;38(2):337-342</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">32202240</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations>
<list>
<country>
<li>Italie</li>
</country>
<region>
<li>Toscane</li>
</region>
<settlement>
<li>Pise</li>
</settlement>
<orgName>
<li>Université de Pise</li>
</orgName>
</list>
<tree>
<country name="Italie">
<region name="Toscane">
<name sortKey="Costagliola, Giorgio" sort="Costagliola, Giorgio" uniqKey="Costagliola G" first="Giorgio" last="Costagliola">Giorgio Costagliola</name>
</region>
<name sortKey="Consolini, Rita" sort="Consolini, Rita" uniqKey="Consolini R" first="Rita" last="Consolini">Rita Consolini</name>
<name sortKey="Spada, Erika" sort="Spada, Erika" uniqKey="Spada E" first="Erika" last="Spada">Erika Spada</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000145 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000145 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidChloroV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:33947420
   |texte=   Severe COVID-19 in pediatric age: an update on the role of the anti-rheumatic agents.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:33947420" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidChloroV1
Wicri

This area was generated with Dilib version V0.6.38.
Data generation: Sat May 22 17:02:32 2021. Site generation: Sat May 22 17:06:52 2021